This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Indonesian Rupiah Plunges 1.2% Against USD, Outpacing Ringgit's Decline
Dec 19, 2024 04:59 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Defining key tasks and accelerating the construction of new urbanization
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Amazon Global Selling: A Decade of Growth in a Vast Market
Dec 17, 2024 05:43 PM
Din Tai Fung and the Globalization of Chinese Cuisine
Dec 03, 2024 08:26 PM
Podcast Marketing, A Useful Tool for Companies Going Overseas
Dec 02, 2024 02:15 PM